Greenwich Lifesciences Valuation
| GLSI Stock | USD 11.11 0.23 2.03% |
At this time, the firm appears to be undervalued. Greenwich Lifesciences retains a regular Real Value of $17.67 per share. The prevalent price of the firm is $11.11. Our model calculates the value of Greenwich Lifesciences from evaluating the firm fundamentals such as Shares Owned By Insiders of 53.05 %, return on asset of -0.9, and Return On Equity of -1.52 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Greenwich Lifesciences' price fluctuation is not too volatile at this time. Calculation of the real value of Greenwich Lifesciences is based on 3 months time horizon. Increasing Greenwich Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Greenwich Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Greenwich Stock. However, Greenwich Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.11 | Real 17.67 | Hype 11.12 | Naive 10.68 |
The intrinsic value of Greenwich Lifesciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Greenwich Lifesciences' stock price.
Estimating the potential upside or downside of Greenwich Lifesciences helps investors to forecast how Greenwich stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Greenwich Lifesciences more accurately as focusing exclusively on Greenwich Lifesciences' fundamentals will not take into account other important factors: Greenwich Lifesciences Total Value Analysis
Greenwich Lifesciences is currently projected to have valuation of 144.68 M with market capitalization of 149.06 M, debt of 294.41 K, and cash on hands of 15.64 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Greenwich Lifesciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
144.68 M | 149.06 M | 294.41 K | 15.64 M |
Greenwich Lifesciences Asset Utilization
One of the ways to look at asset utilization of Greenwich is to check how much profit was generated for every dollar of assets it reports. Greenwich Lifesciences retains a negative application of resources of -0.9 (percent), losing $0.008985 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Greenwich Lifesciences shows how discouraging it operates for each dollar spent on its resources.Greenwich Lifesciences Ownership Allocation
The market capitalization of Greenwich Lifesciences is $149.06 Million. Greenwich Lifesciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Greenwich Lifesciences Profitability Analysis
Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0.About Greenwich Lifesciences Valuation
An absolute valuation paradigm, as applied to Greenwich Stock, attempts to find the value of Greenwich Lifesciences based on its fundamental and basic technical indicators. By analyzing Greenwich Lifesciences's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Greenwich Lifesciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Greenwich Lifesciences. We calculate exposure to Greenwich Lifesciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Greenwich Lifesciences's related companies.Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Greenwich Lifesciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 12.8 M | |
| Shares Float | 5.9 M |
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world |